Yonsei Medical Journal最新文献

{"title":"A Comparison of Symptom Structure between Panic Disorder with and without Comorbid Agoraphobia Using Network Analysis.","authors":"Joonbeom Kim, Yumin Seo, Seungryul Lee, Gayeon Lee, Jeong-Ho Seok, Hesun Erin Kim, Jooyoung Oh","doi":"10.3349/ymj.2024.0177","DOIUrl":"https://doi.org/10.3349/ymj.2024.0177","url":null,"abstract":"<p><strong>Purpose: </strong>Panic disorder (PD) and PD with comorbid agoraphobia (PDA) share similar clinical characteristics but possess distinct symptom structures. However, studies specifically investigating the differences between PD and PDA are rare. Thus, the present study conducted a network analysis to examine the clinical networks of PD and PDA, focusing on panic symptom severity, anxiety sensitivity, anticipatory fear, and avoidance responses. By comparing the differences in network structures between PD and PDA, with the goal of identifying the central and bridge, we suggest clinical implications for the development of targeted interventions.</p><p><strong>Materials and methods: </strong>A total sample (n=147; 55 male, 92 female) was collected from the psychiatric outpatient clinic of the university hospital. We conducted network analysis to examine crucial nodes in the PD and PDA networks and compared the two networks to investigate disparities and similarities in symptom structure.</p><p><strong>Results: </strong>The most influential node within the PD network was Anxiety Sensitivity Index-Revised (ASI-R1; fear of respiratory symptom), whereas Panic Disorder Severity Scale (PDSS5; phobic avoidance of physical sensations) had the highest influence in the PDA network. Additionally, bridge centrality estimates indicated that each of the two nodes met the criteria for \"bridge nodes\" within their respective networks: ASI-R1 (fear of respiratory symptom) and Albany Panic and Phobic Questionnaire (APPQ3; interoceptive fear) for the PD group, and PDSS5 (phobic avoidance of physical sensation) and APPQ1 (panic frequency) for the PDA group.</p><p><strong>Conclusion: </strong>Although the network comparison test did not reveal statistical differences between the two networks, disparities in community structure, as well as central and bridging symptoms, were observed, suggesting the possibility of distinct etiologies and treatment targets for each group. The clinical implications derived from the similarities and differences between PD and PDA networks are discussed.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 5","pages":"277-288"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunologic Response and Effects of COVID-19 Vaccines in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.","authors":"Ki Hyun Lee, Hyunsue Do, Jun Yong Choi, Yong-Beom Park, Sinyoung Kim, Sang-Won Lee, Su Jin Jeong","doi":"10.3349/ymj.2024.0129","DOIUrl":"https://doi.org/10.3349/ymj.2024.0129","url":null,"abstract":"<p><strong>Purpose: </strong>The immunological response and adverse effects of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) in patients receiving coronavirus disease-2019 (COVID-19) vaccines remain unclear. We aimed to evaluate the effects of these vaccines on AAV disease activity.</p><p><strong>Materials and methods: </strong>We reviewed the medical records of 52 patients with AAV who had received at least second doses of the COVID-19 vaccine and evaluated their immunogenicity by measuring the anti-spike (S) antibody (Ab) titer levels using the Roche Elecsys^® immunoassay. Responses to the Birmingham Vasculitis Activity Score (BVAS) tool and 36-Item Short Form Survey before and after vaccination were obtained to assess AAV disease activity. Vaccine reactivity was measured using a standardized questionnaire.</p><p><strong>Results: </strong>We enrolled 52 patients with AAV. No differences were found between those who received second and third doses of vaccination in terms of AAV type, disease activity, vaccine type, or the use of immunosuppressive agents, including steroids. The median anti-S Ab titer was 3967.0 after third doses compared to 419.0 after second doses (<i>p</i>=0.001). Except for mycophenolate mofetil (MMF), when immunosuppressants were administered in conjunction with steroids, the Ab titer was higher after the third vaccination than that after the second dose. The BVAS remained unchanged before and after second and third doses. No life-threatening adverse events were reported.</p><p><strong>Conclusion: </strong>Although COVID-19 vaccine may not produce sufficient antibodies in patients taking MMF, the vaccine did not exacerbate disease activity or cause severe side effects. Therefore, COVID-19 vaccines should be considered in patients with AAV.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 5","pages":"259-268"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144002073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum 25(OH)D Levels and Risk of Nonalcoholic Fatty Liver Disease in Nonobese and Lean Individuals.","authors":"Nam Hee Kim, Ji Hun Kang","doi":"10.3349/ymj.2024.0065","DOIUrl":"https://doi.org/10.3349/ymj.2024.0065","url":null,"abstract":"<p><strong>Purpose: </strong>The impact of vitamin D deficiency on nonalcoholic fatty liver disease (NAFLD) risk in individuals without obesity or insulin resistance has not been thoroughly evaluated. We aimed to identify whether low serum levels of 25(OH)D independently contribute to NAFLD risk in nonobese or lean individuals.</p><p><strong>Materials and methods: </strong>This study analyzed 241208 asymptomatic health check-up examinees who had abdominal ultrasonography. NAFLD risk was evaluated based on obesity status and serum 25(OH)D levels.</p><p><strong>Results: </strong>The overall NAFLD prevalence was 25.5%. Among the 178630 nonobese and 126909 lean participants, the prevalence rates were 13.4% and 6.7%, respectively. The multivariable adjusted odds ratios (ORs) [95% confidence intervals (CI)] for the prevalence of NAFLD, comparing serum 25(OH)D levels of 10-19 and ≥20 ng/mL with <10 ng/mL, were 0.96 (0.93-0.99) and 0.80 (0.77-0.83), respectively. Among nonobese participants, the corresponding adjusted ORs (95% CI) were 0.94 (0.90-0.99) and 0.77 (0.73-0.81), respectively. Similar results were observed among lean participants, with those having a 25(OH)D level of ≥20 ng/mL demonstrating a significantly lower odds of NAFLD (adjusted OR, 0.76; 95% CI, 0.70-0.83). Moreover, these results were consistent even among nonobese and lean individuals who showed no signs of insulin resistance.</p><p><strong>Conclusion: </strong>Insufficient 25(OH)D levels independently increased the risk of NAFLD, suggesting its role in the NAFLD pathogenesis, regardless of obesity or insulin resistance status. Considering the established relationship between vitamin D deficiency and nonobese/lean NAFLD, maintaining adequate 25(OH)D levels may aid in preventing the development of NAFLD, even among nonobese or lean individuals.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 5","pages":"269-276"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144018705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tocilizumab for Patients with Severe Fever with Thrombocytopenia Syndrome: Tocilizumab Observational SFTS Study-1.","authors":"Jeong Rae Yoo, Misun Kim, Myeong Jin Kang, Sora Kim, Keun Hwa Lee, Sang Taek Heo","doi":"10.3349/ymj.2024.0209","DOIUrl":"https://doi.org/10.3349/ymj.2024.0209","url":null,"abstract":"<p><p>There is no established treatment for severe fever with thrombocytopenia syndrome (SFTS). However, the potential role of tocilizumab (TCZ) in cytokine storm modulation warrants further investigation. In this study, we aimed to investigate the therapeutic potential of TCZ in adult patients with SFTS and provide valuable insights into the development of effective treatment strategies for this challenging infectious disease by assessing the impact of TCZ on cytokine dynamics and patient outcomes. This prospective longitudinal observational study included adult patients with SFTS at a teaching hospital in Korea between April 2013 and December 2023. Patients with SFTS and interleukin (IL)-6 levels ≥30 ng/mL received TCZ. The 14- and 28-day mortality rates were compared between the TCZ and therapeutic plasma exchange (TPE) groups during the study period. Among the total of 97 patients, the clinical characteristics showed no significant differences between the TCZ (n=10) and TPE groups (n=30). Compared with TPE, TCZ treatment showed a trend towards lower mortality rate (14-day mortality rate: 10.0% vs. 16.7%, <i>p</i>=0.608; 28-day mortality rate: 10.0% vs. 20.0%, <i>p</i>=0.480). Both treatments showed the potential to reduce the viral load and IL-6 levels, indicating their efficacy in managing the disease course. TCZ is a potential therapeutic option for SFTS as it modulates IL-6 levels and improves clinical outcomes.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 5","pages":"321-327"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors Associated with Middle Ear Barotrauma in Patients Undergoing Monoplace Hyperbaric Oxygen Therapy.","authors":"Yoon Sung Lee, Sang Won Ko, Hyoung Youn Lee, Kyung Hoon Sun, Tag Heo, Sung Min Lee","doi":"10.3349/ymj.2024.0068","DOIUrl":"https://doi.org/10.3349/ymj.2024.0068","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to identify independent risk factors for middle ear barotrauma (MEB) symptoms in patients undergoing monoplace hyperbaric oxygen therapy (HBOT).</p><p><strong>Materials and methods: </strong>We analyzed data from a single-center study involving 296 patients who received monoplace HBOT. Through multivariable logistic regression analysis, we examined the relationship between various factors and the occurrence of MEB to identify significant independent risk factors.</p><p><strong>Results: </strong>The multivariable logistic regression analysis indicated that an altered mental state was associated with increased odds of MEB occurrence [odds ratio (OR) 2.50; 95% confidence interval (CI): 1.13-5.51]. Furthermore, patients in the emergency treatment group for HBOT, as defined by the national health insurance in Korea, were found to be 6.75 times more likely to experience MEB (95% CI: 1.33-34.20).</p><p><strong>Conclusion: </strong>This study identified altered mental status and classification in the emergency treatment group for monoplace HBOT as independent risk factors for MEB. These findings can aid in developing safer protocols for monoplace HBOT chamber operations.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 5","pages":"302-309"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144035107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Failure to Eradicate Infection after Single Arthroscopic Debridement in Septic Arthritis of a Native Knee Joint.","authors":"Junwoo Byun, Min Jung, Kwangho Chung, Se-Han Jung, Hyeokjoo Jang, Chong-Hyuk Choi, Sung-Hwan Kim","doi":"10.3349/ymj.2024.0190","DOIUrl":"https://doi.org/10.3349/ymj.2024.0190","url":null,"abstract":"<p><strong>Purpose: </strong>To identify the risk factors and effect of empirical glycopeptide on the failure of single arthroscopic debridement for septic knee arthritis in a native knee joint.</p><p><strong>Materials and methods: </strong>Patients who underwent arthroscopic debridement for septic knee arthritis from March 2005 to December 2022 at one institution were included in this study. Demographic data, comorbidities, preoperative factors including history of previous surgery, history of injection, laboratory data including preoperative C-reactive protein (CRP) and white blood cell (WBC) count, isolated pathogens from synovial fluid culture, and Gachter stage were analyzed. Statistical analyses using univariate and logistic regression were performed.</p><p><strong>Results: </strong>Out of 132 patients, 17 patients (12.9%) had more than one additional arthroscopic debridement. History of diabetes mellitus (DM) (<i>p</i><0.001), previous injection (<i>p</i>=0.041), isolated <i>Staphylococcus aureus</i> in synovial fluid (<i>p</i>=0.010), and high Gachter stage (<i>p</i>=0.002) were identified as risk factors, whereas age, history of previous knee surgery at the affected knee, CRP level, preoperative WBC, and preoperative neutrophil count of synovial fluid had no significant relation. Logistic regression analysis showed significant increase of risk in patients with DM [odds ratio (OR) 12.002, 95% confidence interval (CI) 3.243-44.418, <i>p</i><0.001], previous injection history (OR 4.812, 95% CI 1.367-16.939, <i>p</i>=0.017), and isolation of <i>Staphylococcus aureus</i> in synovial fluid (OR 4.804, 95% CI 1.282-18.001, <i>p</i>=0.031) as independent risk factors for failure of infection eradication after single arthroscopic debridement.</p><p><strong>Conclusion: </strong>Comorbidity of DM, history of previous injection, isolated <i>Staphylococcus aureus</i> in synovial fluid, and high Gachter stage were associated with a higher risk of failure to eradicate infection with a single arthroscopic procedure. Empirical glycopeptide administration also showed no significant benefit in reducing the risk of additional surgical procedures for infection control, suggesting against the routine administration of glycopeptide.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 5","pages":"295-301"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144026456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovative Approaches in Tracheal Resection and Anastomosis Surgery: Integrating Extracorporeal Membrane Oxygenation for Enhanced Safety.","authors":"Joohyung Son, Bong Soo Son, Jong Myung Park, Jeong Su Cho, Yeongdae Kim, Hoseok I, Do Hyung Kim","doi":"10.3349/ymj.2024.0236","DOIUrl":"https://doi.org/10.3349/ymj.2024.0236","url":null,"abstract":"<p><strong>Purpose: </strong>Tracheal resection with end-to-end anastomosis (TREE) has many advantages over conservative treatment in terms of long-term results; however, this method requires improved safety and accessibility. We aimed to combine expanded venovenous extracorporeal membrane oxygenation (ECMO) during TREE surgery.</p><p><strong>Materials and methods: </strong>Between May 2006 and December 2022, 41 patients diagnosed with tracheal stenosis or tracheal tumors underwent TREE. The non-ECMO and ECMO groups were classified based on the presence or absence of intraoperative ECMO support.</p><p><strong>Results: </strong>Reconstruction length was slightly longer in the ECMO group than in the non-ECMO group, but there was no statistical significance (<i>p</i>=0.082). There was no significant difference between the two groups in terms of operative time (<i>p</i>=0.698), estimated blood loss (<i>p</i>=0.210), and duration of mechanical ventilation (<i>p</i>=0.713). There was a significant difference in intensive care unit stay between the two groups (<i>p</i>=0.013) due to the postoperative maintenance of ECMO. There were no cases of early mortality in either group during hospitalization (<i>p</i>>0.999).</p><p><strong>Conclusion: </strong>ECMO support could assist in more challenging cases as it makes surgery easier in difficult patient scenarios.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 5","pages":"289-294"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mixture of Mastic Gum and Peppermint Extracts Promotes Hair Growth and Health in Vitro and in C57BL/6 Mice.","authors":"Seoyoon Ham, Young In Lee, Yujin Jang, Sang Gu Lee, Jangmi Suk, Inhee Jung, Jae Hyun Park, Ju Hee Lee","doi":"10.3349/ymj.2024.0100","DOIUrl":"https://doi.org/10.3349/ymj.2024.0100","url":null,"abstract":"<p><strong>Purpose: </strong>Hair disorders, which are often attributed to conditions associated with a shortened anagen growth phase, oxidative stress, and hormonal dysregulation, especially during aging, have profound psychological implications. Currently, only minoxidil has been approved as a topical hair growth solution; thus, alternative therapies for treating hair loss and promoting hair health are urgently needed. Herein, we aimed to develop and assess a novel method to promote hair growth and health using mastic (Pistacia lentiscus) gum and peppermint (Mentha piperita L.) extracts.</p><p><strong>Materials and methods: </strong>After determining the optimal ratio of mastic gum and peppermint extracts, we performed in vitro and in vivo experiments to verify the efficacy of the 7:3 mastic gum-peppermint mixture (MP73; FHH-MG) for enhancing hair growth and health.</p><p><strong>Results: </strong>Mastic gum significantly promoted cell proliferation and demonstrated synergistic benefits when combined with peppermint extract. In vitro, FHH-MG increased human dermal follicle papilla cell proliferation and demonstrated anti-inflammatory and antioxidant effects. In vivo, treatment with FHH-MG dose-dependently enhanced hair growth and gloss and increased the expression of vascular endothelial growth factor, epidermal growth factor, β-catenin, and insulin-like growth factor-1 in C57BL/6 mice compared to the negative control.</p><p><strong>Conclusion: </strong>The novel mixture exhibited hair growth-promoting effects in C57BL/6 mice; thus, FHH-MG may serve as a botanical alternative for hair growth and health promotion.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 5","pages":"310-320"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041397/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144018700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep Learning-Based Computer-Aided Diagnosis in Coronary Artery Calcium-Scoring CT for Pulmonary Nodule Detection: A Preliminary Study.","authors":"Seung Yun Lee, Ji Weon Lee, Jung Im Jung, Kyunghwa Han, Suyon Chang","doi":"10.3349/ymj.2024.0050","DOIUrl":"10.3349/ymj.2024.0050","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the feasibility and utility of deep learning-based computer-aided diagnosis (DL-CAD) for the detection of pulmonary nodules on coronary artery calcium (CAC)-scoring computed tomography (CT).</p><p><strong>Materials and methods: </strong>This retrospective study included 273 patients (aged 63.9±13.2 years; 129 men) who underwent CAC-scoring CT. A DL-CAD system based on thin-section images was used for pulmonary nodule detection, and two independent junior readers reviewed the standard CAC-scoring CT scans with and without referencing DL-CAD results. A reference standard was established through the consensus of two experienced radiologists. Sensitivity, positive predictive value, and F1-score were assessed on a per-nodule and per-patient basis. The patients' medical records were monitored until November 2023.</p><p><strong>Results: </strong>A total of 269 nodules were identified in 129 patients. With DL-CAD assistance, the readers' sensitivity significantly improved (65% vs. 80% for reader 1; 82% vs. 86% for reader 2; all <i>p</i><0.001), without a notable increase in the number of false-positives per case (0.11 vs. 0.13, <i>p</i>=0.078 for reader 1; 0.11 vs. 0.11, <i>p</i>>0.999 for reader 2). Per-patient analysis also enhanced sensitivity with DL-CAD assistance (73% vs. 84%, <i>p</i><0.001 for reader 1; 89% vs. 91%, <i>p</i>=0.250 for reader 2). During follow-up, lung cancer was diagnosed in four patients (1.5%). Among them, two had lesions detected on CAC-scoring CT, both of which were successfully identified by DL-CAD.</p><p><strong>Conclusion: </strong>DL-CAD based on thin-section images can assist less experienced readers in detecting pulmonary nodules on CAC-scoring CT scans, improving detection sensitivity without significantly increasing false-positives.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 4","pages":"240-248"},"PeriodicalIF":2.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143711458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Factors for Increased Bone Density Following Romosozumab Administration Based on Pre-Administration Blood Test Results.","authors":"Akira Kuwabara, Kazuhide Inage, Masaomi Yamashita, Sumihisa Orita, Yawara Eguchi, Yasuhiro Shiga, Masahiro Inoue, Miyako Suzuki-Narita, Takahisa Hishiya, Takahito Arai, Noriyasu Toshi, Kohei Okuyama, Soichiro Tokeshi, Susumu Tashiro, Shuhei Ohyama, Noritaka Suzuki, Seiji Ohtori","doi":"10.3349/ymj.2023.0535","DOIUrl":"10.3349/ymj.2023.0535","url":null,"abstract":"<p><strong>Purpose: </strong>Romosozumab reportedly increases bone density in patients with severe osteoporosis; however, data on its clinical effects are limited. We conducted a multicenter retrospective survey to study the bone density-increasing effects of romosozumab and blood test-based predictive factors in patients with severe osteoporosis, examining its effects in clinical practice.</p><p><strong>Materials and methods: </strong>This was a multicenter retrospective observational study. The subjects were patients with severe osteoporosis who were treated with romosozumab at the participating facilities. The increase in bone density was assessed by comparing bone density changes (as a percentage) in the lumbar spine, femoral neck, and total femur before and 12 months after administration using dual-energy X-ray absorptiometry. The association between changes in bone density at each site and pre-treatment bone metabolism markers (Tracp 5b, P1NP), serum calcium levels, nutritional status [Conut score: albumin, total cholesterol (T-Cho), and total lymphocyte count], and kidney function (eGFR) was assessed.</p><p><strong>Results: </strong>In both naïve patients and those switching from bone resorption inhibitors, the bone density increased significantly. In naïve patients, eGFR were positively associated with bone density in the total femur. In cases of switching from bone resorption inhibitors, correlations were found between Tracp 5b and lumbar spine bone mineral density (BMD), as well as between Tracp 5b, Alb, T-Cho, and eGFR in the total femur BMD.</p><p><strong>Conclusion: </strong>Romosozumab administration significantly increases bone density in osteoporosis, and assessing key predictive factors is necessary to ensure clinical effectiveness.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 4","pages":"226-232"},"PeriodicalIF":2.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955392/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}